Innate Pharma SA
IPHA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001598599
No open-market purchases or sales by Innate Pharma SA insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $354.0K in total; no superinvestor holds it.
Other share classesIPHYF
Q1 2022 vs. Q4 2021
How the institutions holding Innate Pharma SA changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 16 | 13 | −3 |
| Shares | 1.39M | 952.3K | −437.9K (−31.5%) |
| Value | $6.52M | $3.20M | −$3.32M (−50.9%) |
New holders (2)
Institutions that held Innate Pharma SA at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Barclays PLC | 3,411 | $11.0K | 0.00% |
| Captrust Financial Advisors | 905 | $3.00K | 0.00% |
Sold out (5)
Institutions that held Innate Pharma SA at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Silverarc Capital Management, LLC | 184,046 | $839.0K |
| Pura Vida Investments, LLC | 79,896 | $364.0K |
| Two Sigma Advisers, LP | 12,300 | $56.0K |
| Virtu Financial LLC | 11,740 | $54.0K |
| Tower Research Capital LLC (TRC) | 410 | $2.00K |